ArticleDiscover oncology2025
LINC00519 promotes the progression of cholangiocarcinoma through regulating the axis of miR-876-3p/GATA1.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDue to its lack of early symptoms, cholangiocarcinoma (CCA) is frequently diagnosed at advanced stages, contributing to its dismal prognosis. Therefore, it is necessary to find new, efficient therapeutic methods for the disease. This study excavated the role of LINC00519 in CCA progression, aiming to provide useful insights into CCA treatment. MATERIALS AND
methodsThis study collected tumor and normal paracancer tissues from CCA patients (n = 202) to explore the prognostic significance of LINC00519 in CCA. CCA cell lines CCLP1 and QBC939 were employed for detecting the role of LINC00519 on CCA tumor development. The qRT-PCR was used to measure the expression of biomolecules. Cell Counting Kit-8 (CCK-8) and transwell assay were used to estimate CCA cell proliferation, migration and invasion. Binding sites between biomolecules were verified using a dual luciferase reporter assay.
resultsLINC00519 was upregulated in CCA. The upregulation of LINC00519 was associated with poor prognosis and serverity in CCA patients. LINC00519 facilitated CCA progression by promoting CCA cell proliferation rate, as well as cell migration and invasion ability. The approach for LINC00519 altering CCA cell activities was to inhibit miR-876-3p, and miR-876-3p could further negatively regulate GATA1.
conclusionLINC00519 upregulation may serve as a potential indicator of CCA aggravation. LINC00519 promoted CCA development by targeting miR-876-3p to affect cancer cell activities. GATA1, a potential target of miR-876-3p, suggests the potential underlying molecular pathway. Targeting LINC00519 could be an efficient way to manage CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.